Tresa Reena Mascarenhas, MBBS

Tresa Mascarenhas practices at ChristianaCare Wilmington Hospital in Wilmington, Delaware.

Tresa Mascarenhas' NPI, 1477846079, was assigned on May 16, 2011. Tresa Mascarenhas holds Delaware license C10011090.

Tresa Mascarenhas' primary practice is ChristianaCare Wilmington Hospital, at 501 W 14th St, Wilmington, DE 19801 in New Castle County. The practice phone is (302) 733-1000.

Tresa Mascarenhas' primary practice is ChristianaCare Wilmington Hospital in Wilmington, Delaware. Tresa Mascarenhas is also affiliated with Saint Francis Hospital. The medical group on file is Infectious Disease Consultants. Dmand AI also links Tresa Mascarenhas to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tresa Mascarenhas practices, 5 sites in all. Vendor and product names are available with a free account.

Infectious disease is Tresa Mascarenhas' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Tresa Mascarenhas is licensed in Delaware.

CMS data shows 1,070 Medicare services from Tresa Mascarenhas across 6 procedure codes in 2024, for 324 Medicare patients. Medicare paid $96,353 for them.

CMS counts 324 Medicare patients who saw Tresa Mascarenhas in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 3.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Tresa Mascarenhas' median patient age at 69, with 47% women.

In 2024, Tresa Mascarenhas wrote 603 Medicare Part D claims for 96 patients. 67% of them were for generic drugs. CMS names the drug for 455 of them, across 21 drugs with 11 or more claims each, at $715,877 in total drug cost. In 2023, CMS named 410 claims across 23 drugs.

Tresa Mascarenhas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Tresa Mascarenhas as offering telehealth.

Dmand AI links 1 paper to Tresa Mascarenhas in 2018. Tresa Mascarenhas' most frequent co-authors are Katherine A. Belden, MD and Randi S. Silibovsky, MD.

CMS Open Payments shows 27 general payments to Tresa Mascarenhas from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 77% of the total. Merck Sharp & Dohme Corporation paid the most, $159.